Etalocib

Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis[1][2][3].

Product Specifications

CAS Number

[161172-51-6]

Product Name Alternative

LY293111; VML 295

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Leukotriene Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/etalocib.html

Purity

99.03

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=CC=C1OC2=CC=CC(OCCCOC3=C(CC)C=C(C4=CC=C(F)C=C4)C(O)=C3)=C2CCC

Molecular Formula

C33H33FO6

Molecular Weight

544.61

Precautions

H302, H315, H319, H335

References & Citations

[1]P Marder, et al. Blockade of Human Neutrophil Activation by 2-[2-propyl-3-[3-[2-ethyl-4- (4-fluorophenyl) -5- Hydroxyphenoxy]propoxy]phenoxy]benzoic Acid (LY293111), a Novel Leukotriene B4 Receptor Antagonist. Biochem Pharmacol. 1995 May 26;49 (11) :1683-90.|[2]S A Silbaugh, et al. Pharmacologic Actions of the Second Generation Leukotriene B4 Receptor Antagonist LY29311: In Vivo Pulmonary Studies. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361 (4) :397-404.|[3]Wei-Gang Tong, et al. Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells. Clin Cancer Res. 2002 Oct;8 (10) :3232-42.